Abstract
Get full access to this article
View all access options for this article.
References
1.
Olde Bekkink
M
Ahmed-Ousenkova
YM
Netea
MG
Van der Velden
WJ
Berden
JH
. Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: Coincidence or correlated? Lupus 2016 ; 25 : 766 –771 .
2.
Singh
N
Birkenbach
M
Caza
T
Perl
A
Cohen
PL
. Tuberous sclerosis and fulminant lupus in a young woman . J Clin Rheumatol 2013 ; 19 : 134 –137 .
3.
Katada
Y
Maeda
Y
Yoshimura
M
. Coincidence of tuberous sclerosis and systemic lupus erythematosus . Mod Rheumatol 2012 ; 22 : S155 –S155 .
4.Carrasco Cubero C, Bejarano Moguel V, Fernández Gil MÁ, Álvarez Vega JL. Asociación lupus eritematoso sistémico y esclerosis tuberosa un caso. (Coincidence of tuberous sclerosis and systemic lupus erythematosus: A case report.) Reumatol Clin 2016; 12: 219–222 .
5.Carr Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol 2016; 12: 169–82 .
6.
Yap
DY
Ma
MK
Tang
CS
Chan
TM
. Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience . Nephrology 2012 ; 17 : 676 –680 .
7.US National Library of Medicine. NCT00779194, https://clinical trials.gov/ct2/results?term¼NCT00779194 (accessed 1 June 2016) .
8.
Tee
AR
Sampson
JR
Pal
DK
Bateman
JM
. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex . Semin Cell Dev Biol 2016 ; 52 : 12 –20 .
9.
MacKeigan
JP
Krueger
DA
. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex . Neuro Oncol 2015 ; 17 : 1550 –1559 .